Category: Venture Capital
Dr. Thomas Graham, surgeon to professional athletes, hired as chief of the corporate ventures arm of the Cleveland Clinic.
By Mary Vanac
Renown hand surgeon to professional athletes, Dr. Thomas Graham, is returning to Cleveland as chief of Cleveland Clinic Innovations, the corporate venturing unit of the Cleveland Clinic.
Nashua, N.H.-based DiagnosisONE lands a $5 million investment from New Jersey-based Edison Venture Fund to expand sales, marketing and development operations for its HIT offering.
DiagnosisONE landed a $5 million investment from a New Jersey venture capital firm to build out its sales, marketing and development operations.
The Nashua, N.H.-based company makes software to help healthcare providers manage diagnostics data.
The Cleveland Clinic's venture capital arm makes the top ranks of healthcare VC firms, according to Global Corporate Venturing.
By Mary Vanac
Cleveland Clinic Innovations — the corporate venturing arm of the nation's top heart hospital — is entering its second decade with a first-of-its-kind venture ranking, a brand-new incubator building and a growing portfolio of spin-out companies.
Venerable venture capital firm Venrock puts together a $350 million fund, more than 40 percent smaller than its last, $600 million investment pool.
By Brandon Glenn
Jumping on the venture capital industry's less-is-more bandwagon, Venrock put together a $350 million fund, down more than 40 percent from its last funding pool.
SV Life Sciences raises the year’s second-largest life sciences fund, beating a target of $400 million to close with $523 million in commitments.
By Brandon Glenn
SV Life Sciences raised the year's second-largest life sciences fund thus far, exceeding its targeted amount to close with $523 million in commitments.
The firm originally planned to raise $400 million, but attributed its fundraising success in today's “challenging environment” to its past success, according to a statement.
Not that there's anything wrong with that. The IN3 Investor's conference reveals a new breed of venture capitalists, who see lean as the new black.
The new mantra of the venture capitalist is capital efficiency.
I must have heard that six or seven times while attending the IN3 investor's conference in Boston this week. The event, put on by Elsevier Business Intelligence, brings together startups, established companies and venture capitalists; three interdependent partners with competing interests. After all, the startups want to get the VCs' money, who don't want to give it to them. The VCs want to sell their companies to the big companies, who don't want to give them the valuations they want. And everyone wants to sell their company to Boston Scientific Corp. (NYSE:BSX) or Covidien plc (NYSE:COV).
Arboretum Ventures' Dr. Brian Duncan, a former pediatric heart surgeon, on making the change to the venture world and the Midwest's medical device start-up scene.
By Mary Vanac
Dr. Brian Duncan caught the business bug as the only clinician on a team of Cleveland Clinic researchers who set out in 2004 to develop a heart-assist pump for infants with heart failure.